When successful, this approach can work wonders, but most cancers are far more complex than CML, which has just a single mutant gene.
At least a fraction of patients treated with targeted drugs (assuming they respond at all) will develop drug resistance as tumor cells mutate to utilize other growth-promoting pathways.